| 2RGU | date | ![]() |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| authors | |||||||||||||||
| compound | source | ||||||||||||||
| symmetry |
| ||||||||||||||
| crystal cell |
| ||||||||||||||
| method | X-Ray Diffraction | resolution | |||||||||||||
| ligand | 356, NAG BindingDB | enzyme |
| ||||||||||||
| Gene Ontology |
| ||||||||||||||
| Primary reference | 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin -2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes., Eckhardt M, Langkopf E, Mark M, Tadayyon M, Thomas L, Nar H, Pfrengle W, Guth B, Lotz R, Sieger P, Fuchs H, Himmelsbach F, J Med Chem. 2007 Dec 27;50(26):6450-3. Epub 2007 Dec 1. PMID:18052023 | ||||||||||||||
| Data retrieval |
![]() |
| View 2RGU in 3D |
Proteopedia, because life has more than 2D. |
| Structure-derived information |
| Sequence-derived information |
|
OCA© by Jaime Prilusky, 1996-2014,2022,2024 Bioinformatics Unit Weizmann Institute of Science |